title: [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
abstract: Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil, tadalafil and vardenafil are first line treatment for erectile dysfunction (ED). These PDE5 inhibitors are known to increase cyclic guanosine monophosphate (cGMP) concentrations in the smooth muscle cells of the corpora cavernosa penis by inhibiting PDE5, leading to smooth muscle relaxation. This mode of action is also believed to result in prostatic smooth muscle relaxation and to improve lower urinary tract symptoms (LUTS). Randomized controlled trials have shown beneficial effects on LUTS and on objective parameters such as maximum urinary flow rate (tadalafil). Based on these data tadalafil was recently approved for treatment of patients with male LUTS; however, the mechanisms leading to improvement of symptoms are still under debate.
authors: Urologische Klinik und Poliklinik, Klinikum der Universität München-Großhadern, Marchioninistraße 15, Munich, Germany. annika.herlemann@med.uni-muenchen.de
authors: A
authors: A
authors: Herlemann
authors: C
authors: C
authors: Gratzke
authors: K-E
authors: KE
authors: Andersson
authors: K D
authors: KD
authors: Sievert
mesh_terms: D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D006152:Cyclic GMP / Q000378:metabolism; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000378:metabolism; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use; D000068581:Tadalafil; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use; D014563:Urodynamics / Q000187:drug effects; D000069058:Vardenafil Dihydrochloride
chemical_list: D002243:Carbolines; D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006152:Cyclic GMP